Merck's Zostavax cuts the incidence of shingles by half and was approved in May 2006 for people 60 and up.

FORBES: Magazine Article

Production problems led to a backlog in orders for Zostavax, for shingles.

FORBES: Magazine Article

Merck (nyse: MRK - news - people )'s Zostavax cuts the incidence of shingles by half and was approved in May 2006 for people 60 and up.

FORBES: Shots for Grown-Ups